NCT00648050View on ClinicalTrials.gov

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Healthy
Interventions
DRUG

Verapamil Hydrochloride Extended-Release Capsules, 300 mg

300mg, single dose fasting

DRUG

Verelan® PM Extended-Release Capsules, 300 mg

300mg, single dose fasting

Trial Locations (1)

58104

PRACS Institute, Ltd., Fargo

Sponsors
All Listed Sponsors
lead

Mylan Pharmaceuticals Inc

INDUSTRY

NCT00648050 - Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg | Biotech Hunter | Biotech Hunter